If the advisers do not endorse a broad authorization for people 18 and older in next week’s meetings, the FDA’s fallback position might be to authorize boosters for people 40 and older, as well as younger people with medical conditions, jobs or living situations that make them more vulnerable to covid-19, according to people familiar with the FDA’s thinking who spoke on the condition of anonymity because they did not have authorization to discuss internal plans.